HSCI / Hong Kong Connect Inclusion (March 2026): A Preliminary Assessment
We assess stocks potentially eligible for inclusion in the upcoming HSCI review and outline the resulting Hong Kong Stock Connect eligibility...
576 Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
961 Views
Innogen (银诺医药) IPO: Fairly Valued at Best and Lack of Institutional Interests
China biotech company Innogen launches IPO in Hong Kong to raise at least $88 million, with a demanding valuation and lack of institutional...
689 Views
Innogen (银诺医药) Pre-IPO Update: Cuts in Market Forecasts
China biotech company Innogen plans to raise $100 million in Hong Kong listing with CITIC Securities and CICC as joint sponsors, with scaled down...
543 Views
Innogen (银诺医药) Pre-IPO Update: New Data Points
China-based biotech company Innogen seeks to raise $100 million through Hong Kong listing. We look at updates from the company's latest prospectus...
572 Views